ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(0.85) per share. This is a 325 percent decrease over losses of $(0.20) per share from the same period last year.
Clinical Collaboration Agreement between Teva And Launch Therapeutics To Accelerate Development Of Dual-Action Asthma Rescue Inhaler Respiratory Program; Teva And Abingworth Enter Strategic Development Funding Agreement To Provide Up To $150M To Offse…
Collaboration combines Teva's expertise in respiratory technology development and Launch Therapeutics' innovative late-stage drug development model to progress Teva's Dual-Action Asthma Rescue Inhaler (TEV-‘248)
